Iron Chelation Therapy Market Report 2026

Iron Chelation Therapy Market Overview

• Iron Chelation Therapy market size has reached to $2.68 billion in 2025 • Expected to grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rise In Blood Transfusions Fueling The Growth Of The Market Due To Increasing Surgical Complexity And Chronic Disease Burden • Market Trend: Advancing Iron Overload Management With Next-Generation Extended-Release Chelators • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Iron Chelation Therapy Market?

Iron chelation therapy refers to a medical treatment designed to remove excess iron from the body in patients with conditions that require frequent blood transfusions or have iron overload disorders. This therapy involves the use of chelating agents that bind to excess iron, allowing it to be excreted from the body, usually through urine or feces. It is used in the management of thalassemia, sickle cell disease, and other chronic anemias to prevent organ damage and improve long-term patient outcomes. The main types of iron chelation therapy are deferasirox, deferoxamine, and deferiprone. Deferasirox is an oral chelating agent commonly used to eliminate excess iron in patients undergoing frequent blood transfusions due to conditions such as beta-thalassemia and other chronic anemias. The therapy can be administered through various routes, including oral, parenteral, intravenous, and subcutaneous methods. Key indications for its use include thalassemia, sickle cell disease, myelodysplastic syndromes (MDS), and non-transfusion-dependent thalassemia (NTDT). It is suitable for a broad patient population, including pediatric, adult, elderly, and gender-specific groups such as male and female, and is used by various end users such as hospitals, specialty clinics, homecare settings, and others.

What Is The Iron Chelation Therapy Market Growth Forecast?

The iron chelation therapy market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing adoption of patient-centric treatment regimens, rising development of next-generation chelators, expansion of home-based iron management, growing focus on reducing therapy side effects, increasing investments in rare disease therapeutics. Major trends in the forecast period include increasing preference for oral chelation therapies, rising focus on patient adherence and compliance, growing use of personalized iron management plans, expansion of long-term iron overload monitoring, enhanced development of modified-release formulations.

Global Iron Chelation Therapy Market Segmentation

1) By Drug Type: Deferasirox, Deferoxamine, Deferiprone 2) By Route Of Administration: Intravenous Administration, Subcutaneous Delivery 3) By Indication: Thalassemia, Sickle Cell Disease, Myelodysplastic Syndromes (MDS), Non-Transfusion-Dependent Thalassemia (NTDT) 4) By Patient Demographics: Pediatric Patients, Adult Patients, Elderly Patients 5) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Other End-Users Subsegments: 1) By Deferasirox: Dispersible Tablets (DT), Film-Coated Tablets (FCT), Oral Suspension 2) By Deferoxamine: Injectable Solution, Subcutaneous Infusion, Intramuscular Injection, Intravenous Infusion 3) By Deferiprone: Oral Solution, Oral Tablets, Modified-Release Tablets

What Is The Driver Of The Iron Chelation Therapy Market?

The increasing blood transfusions are expected to propel the growth of the iron chelation therapy market going forward. Blood transfusion involves giving a patient donated blood to restore blood volume or treat specific health conditions, such as anemia or blood loss. The rise in blood transfusions is due to the increasing prevalence of complex surgeries, which often involve significant blood loss requiring transfusion to maintain hemodynamic stability and support patient recovery. Iron chelation therapy is used to remove excess iron that accumulates in the body due to frequent blood transfusions. For instance, according to the American Red Cross, a US-based non-profit organization, each year in the U.S., about 16 million blood components are transfused. Sickle cell disease affects 90,000 to 100,000 people, with around 1,000 babies born with it annually, and many patients need lifelong blood transfusions. Therefore, the increasing blood transfusions are driving the growth of the iron chelation therapy industry.

Key Players In The Global Iron Chelation Therapy Market

Major companies operating in the iron chelation therapy market are Novartis AG, Bayer AG, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Cipla Ltd., Zydus Cadila, Natco Pharma Ltd., Apotex Inc., Mylan NV (Viatris Inc.), Chiesi Farmaceutici S.pA., Lupin Limited, Taro Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., Accord Healthcare, Sandoz International GmbH, Recordati S.p.A., Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Keryx Biopharmaceuticals Inc.

Global Iron Chelation Therapy Market Trends and Insights

Major companies operating in the iron chelation therapy market are focusing on developing next-generation chelators with enhanced bioavailability to improve treatment efficacy, reduce side effects, and increase patient adherence. Next-generation chelators with enhanced bioavailability are designed to improve the absorption and efficacy of iron chelation therapies, aiming to optimize dosing schedules and increase patient compliance in managing iron overload disorders. For instance, in March 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical company, received approval from Health Canada for its FERRIPROX MR, a twice-daily extended-release iron chelator, to treat iron overload in patients with thalassemia, sickle cell disease, and other anemias, offering improved convenience and continued support for rare disease care. Clinical data support that FERRIPROX MR 1,000 mg is effective and safe for the target population, with a safety profile considered acceptable for patients with iron overload.

What Are Latest Mergers And Acquisitions In The Iron Chelation Therapy Market?

In September 2024, Mitem Pharma, a France-based pharmaceutical company, acquired the worldwide rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. With this acquisition, Mitem Pharma aims to expand its presence in the iron chelation therapy sector and enhance its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG is a Switzerland-based pharmaceutical company that offers iron chelation therapy.

Regional Outlook

North America was the largest region in the iron chelation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Iron Chelation Therapy Market?

The iron chelation therapy market includes revenues earned by entities by providing services such as clinical trial management, personalized treatment planning, drug development, and monitoring iron levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron chelation therapy market also includes sales of injectable iron chelators, extended-release formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Iron Chelation Therapy Market Report 2026?

The iron chelation therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the iron chelation therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.